Novel selective multikinase inhibitors of ROCK and MRCK have been reported to efficiently block migration and invasion of various metastatic cancer cells, including melanoma, pancreatic, breast, and colorectal cancer cell lines (Kale et al., 2014; Gandalovičová et al., 2017; Poisson et al., 2020). This evidence concerns the gene CDC42BPA and metastatic malignant neoplasm.